WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq:EGRX) today announced that the Company has been named to the Fortune 100 List of Fastest-Growing Companies, ranking 16thoverall, including achieving the #1 positions for EPS 3-year growth of 392% and revenue 3-year growth of 109%.
“We are extremely proud of how our team has executed on our overall growth strategy. We continue to see excellent opportunities ahead for our business,” stated Scott Tarriff, Chief Executive Officer of Eagle Pharmaceuticals.
Fortune's list ranks public companies, with market capitalization of $250 million or more, based on revenue growth rate, EPS growth rate and three-year annualized total return for the period ended June 30, 2018.
About Eagle Pharmaceuticals, Inc.
Eagle is a specialty pharmaceutical company focused on developing and commercializing injectable products that address the shortcomings, as identified by physicians, pharmacists and other stakeholders, of existing commercially successful injectable products. Eagle’s strategy is to utilize the FDA's 505(b)(2) regulatory pathway. Additional information is available on the company’s website at www.eagleus.com.
